ClinicalTrials.gg
CompletedNCT04147572TIOPIFUpdated Jan 27, 2020

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler

An interventional study of Placebo Tiotropium inhalation powder type A and Placebo Spiriva capsule in Healthy Volunteer and COPD, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Estonia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Orion Corporation, Orion Pharma · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Estonia.

Enrollment
38th of 42
200 · median 730
Started
2019
with 2 others
No phase
4 of 42
none open now
Registered
37th of 42
by date
Lead sponsor
2 of 42
Orion Corporation, Orion Pharma

Among the 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia, this one is the 38th largest by enrollment, is one of 3 that started in 2019, is one of 4 with no phase, and was the 37th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia is open now. Recruiting first, the newest first:

A study can be open while its sites in Estonia have not opened yet or have stopped. Only those recruiting at a site in Estonia →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Pulmonary Disease, Chronic Obstructive with a site in Estonia, or all of them as a file.
02

Study summary

The study will characterise inspiratory flow parameters across placebo dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via HandiHaler in patients with chronic obstructive pulmonary disease (COPD) and in healthy volunteers.

Substudy: Easyhaler® and HandiHaler® Usability study in patients with COPD; to assess patients acceptability, preference, correct use and ability to learn to use Easyhaler and HandiHaler (with capsules) and to compare PIF rate via In-Check Dial meter with the PIF rate via spirometer in the main study.

Read the detailed description

This is an open, randomised, multicentre, crossover study with Easyhaler and HandiHaler inhalers. The primary objective is to characterise inspiratory flow parameters across placebo dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via HandiHaler in patients with chronic obstructive pulmonary disease (COPD) and in healthy volunteers. The secondary objective is to calculate correlation of peak inspiratory flow (PIF) rate with regards to anthropometric and lung function parameters.

Substudy: This is an open, randomised, multicentre, crossover study with Easyhaler and HandiHaler inhalers.There will be 1 study visit per subject, usually this visit is done at the same visit with the main study.

03

Conditions studied

  • Healthy Volunteer
  • COPD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for subjects with :

  1. Written (IC) obtained.
  2. ≥18 years of age.
  3. Documented diagnosis of COPD.

Inclusion Criteria for healthy volunteers:

  1. Written informed consent (IC) obtained.
  2. ≥18 years of age.
  3. at least 80% of the predicted value measured at screening.
  4. Good general health ascertained by medical history.

Exclusion Criteria for subjects with COPD:

  1. Any chronic respiratory disease other than COPD.
  2. Acute respiratory infection.
  3. Concurrent participation in a clinical drug study.
  4. Any medical condition (e.g. to spirometry) that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject if he/she participates in the study. E.g. any concomitant disease in clinically labile state judged by the investigator.
  5. Severe milk allergy (lactose contains small amounts of milk proteins).

Exclusion Criteria for healthy volunteers:

  1. Evidence of a cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease within the previous 2 years.
  2. Acute respiratory infection.
  3. Concurrent participation in a clinical drug study.
  4. Any medical condition (e.g. contraindications to spirometry) that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject if he/she participates in the study.
  5. Severe milk allergy (lactose contains small amounts of milk proteins).

Substudy:

Patients with documented diagnosis of COPD aged 18 year or older participating the main study will be enrolled in this substudy. Written informed consent (IC) will be obtained.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Inhaler A, Tiotropium Easyhaler

    Placebo Tiotropium Easyhaler, type A

    Drug: Placebo Tiotropium inhalation powder type A

  • Experimental
    Inhaler B, Tiotropium Easyhaler

    Placebo Tiotropium Easyhaler, type B

    Drug: Placebo Tiotropium inhalation powder type B

  • Placebo comparator
    Reference product, Spiriva modified HandiHaler

    Placebo Spiriva, hard capsule inhaled via modified HandiHaler device

    Drug: Placebo Spiriva capsule

  • Experimental
    Substudy Test product Placebo Tiotropium Easyhaler

    The substudy subjects will demonstrate the use of the inhaler.

    Device: Substudy Placebo Tiotropium Easyhaler

  • Placebo comparator
    Substudy Reference product Placebo Spiriva® HandiHaler

    The substudy subjects will demonstrate the use of the inhaler.

    Device: Substudy Placebo Spiriva® via HandiHaler

Interventions

  • DrugPlacebo Tiotropium inhalation powder type A

    Placebo inhalation from inhaler A

  • DrugPlacebo Spiriva capsule

    Placebo inhalation from HandiHaler

  • DrugPlacebo Tiotropium inhalation powder type B

    Placebo inhalation from inhaler B

  • DeviceSubstudy Placebo Tiotropium Easyhaler

    Substudy placebo inhalation

  • DeviceSubstudy Placebo Spiriva® via HandiHaler

    Substudy placebo inhalation

06

What researchers measure

Primary outcomes

  1. The primary variable will be the PIF rate through the Easyhaler and HandiHaler inhalers.

    After practising, 3 inspiratory flow curves will be recorded and the inhalation with the highest PIF rate analysed.

    Time frame: 1 day

Secondary outcomes

  1. Inspiratory volume through the Easyhaler and HandiHaler inhalers

    Highest inspiratory volume recorded and analysed from the same inhalation as the PIF rate.

    Time frame: 1 day

Other outcomes

  1. Correct use of Easyhaler and HandiHaler tabulated by frequencies and percents based on the inhaler specific questionnaire, assessed by the site staff.

    Substudy outcome

    Time frame: 1 day

  2. Patient's acceptability of inhalers, assessed by the study specific questionnaire

    Substudy outcome

    Time frame: 1 day

  3. Patient's preference of inhalers assessed by study specific questionnaire

    Substudy outcome

    Time frame: 1 day

  4. Patient's ability to learn the use of the inhalers, assessed by the study specific questionnaire.

    Substudy outcome

    Time frame: 1 day

  5. Peak inspiratory flow measurement via In-Check Dial

    Substudy outcome

    Time frame: 1 day

07

Study locations

1 site
  • Lung Clinic, Tartu University Hospital
    Tartu, Estonia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2020, 2 months.

Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 2 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2019
First posted
Nov 1, 2019
StartActual
Nov 1, 2019
Primary completionActual
Jan 13, 2020
CompletionActual
Jan 13, 2020
Last update
Jan 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04147572
Responsible party
Sponsor
First posted
Nov 1, 2019
Start date
Nov 1, 2019
Primary completion
Jan 13, 2020
Completion
Jan 13, 2020
Last update
Jan 27, 2020

Study contacts

Orion Pharma Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion